Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus medication litifilimab. In return, Royalty Pharma will receive undisclosed ...

July 10, 2024 — Scientists have discovered a molecular defect that promotes the pathologic immune response in systemic lupus erythematosus (known as lupus) and show that reversing this defect ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Medically reviewed by Brendan Camp, MD Polymorphic light eruption (PMLE), commonly known as a sun rash or sun poisoning, is a ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role in cutaneous autoimmune diseases, such as cutaneous lupus erythematosus (CLE ...

Current treatment options for systemic lupus erythematosus (SLE ... is being treated for a disease flare or shortly thereafter. Drugs most commonly used in this setting are antimalarials and ...

Hypoglycemia (low blood sugar) is not a formal symptom of lupus, but it may develop from related factors like medication use, other autoimmune processes in the body, and hormonal changes.

BACKGROUND: Statins have been increasingly associated with drug-induced autoimmune reactions, including lupus erythematosus. OBJECTIVE: To identify and determine the clinical and biological ...

An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus .